Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect

Umair Majeed; Tudor Puiu; Jason Sluzevich; Gina Reynolds; Marites Acampora; Alvaro Moreno-Aspitia; Katherine J Bodiford; Pooja Advani

doi:10.3389/fonc.2021.726785

Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect

Front Oncol. 2021 Aug 24:11:726785. doi: 10.3389/fonc.2021.726785. eCollection 2021.

Authors

Umair Majeed¹, Tudor Puiu², Jason Sluzevich², Gina Reynolds¹, Marites Acampora¹, Alvaro Moreno-Aspitia¹, Katherine J Bodiford², Pooja Advani¹

Affiliations

¹ Division of Hematology Oncology, Mayo Clinic Florida, Jacksonville, FL, United States.
² Division of Dermatology, Mayo Clinic Florida, Jacksonville, FL, United States.

Abstract

Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and systemic symptoms (DRESS) upon initial exposure to alpelisib. Here we describe the clinical-pathological findings and management of our patient with alpelisib-induced life-threatening DRESS syndrome. The goal of this case report is to highlight association of alpelisib with DRESS syndrome, in clinical practice, so that alpelisib can be immediately stopped and treatment for this serious condition promptly initiated.

Keywords: DRESS; PI3K inhibitor therapy; alpelisib; breast cancer; drug rash.

Publication types

Case Reports